Zacks Industry Outlook Spotlights Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals, and Twist BioScience
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Sep 24 2025
0mins
Source: NASDAQ.COM
Biotech Industry Overview: The biotech sector has shown resilience in 2025, with significant investments in U.S. manufacturing amid tariff threats, and a surge in mergers and acquisitions driven by AI-driven drug discovery and the need for innovative treatments.
Key Companies to Watch: Halozyme Therapeutics, Akero Therapeutics, Kiniska Pharmaceuticals, ANI Pharmaceuticals, and Twist BioScience are highlighted as companies poised to outperform the sector, with strong growth prospects and strategic collaborations enhancing their market positions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy TWST?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on TWST
Wall Street analysts forecast TWST stock price to fall over the next 12 months. According to Wall Street analysts, the average 1-year price target for TWST is 41.25 USD with a low forecast of 39.00 USD and a high forecast of 43.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
5 Analyst Rating
5 Buy
0 Hold
0 Sell
Strong Buy
Current: 42.600
Low
39.00
Averages
41.25
High
43.00
Current: 42.600
Low
39.00
Averages
41.25
High
43.00
About TWST
Twist Bioscience Corporation is a synthetic biology and genomics company that has developed a deoxyribonucleic acid (DNA) synthesis platform to industrialize the engineering of biology. The Company's platform's core is a proprietary technology that specializes in manufacturing synthetic DNA by writing DNA on a silicon chip. It has applied its technology to manufacture a range of synthetic DNA-based products, including synthetic genes, tools for next generation sequencing (NGS) sample preparation, and antibody libraries for drug discovery and development, all designed to enable its customers to conduct research. Its gene products include multiplexed gene fragments, express genes, clonal genes and gene fragments. The Company also manufactures synthetic ribonucleic acid (RNA) as well as antibody proteins. The Company's synthetic DNA tools are used in fields, such as medicine, agriculture, industrial chemicals and defense. It has minority ownership in Atlas Data Storage, Inc.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Planet Labs PBC Secures Nine-Figure Deal with Swedish Armed Forces, Shares Surge 7%
- Stock Surge: Planet Labs PBC's announcement of a multi-year nine-figure agreement with the Swedish Armed Forces led to a 7% increase in share price to $24.29 on Monday, reflecting strong market confidence in the company's long-term contracts.
- Revenue Outlook Boost: Day One Biopharmaceuticals Inc reported preliminary 2025 OJEMDA net product revenue of $155.4 million, up 172% year-over-year, indicating robust growth potential in the biopharmaceutical sector that may attract more investor interest.
- Market Dynamics: Amid a broader decline in U.S. stocks, Wheels Up Experience Inc saw its shares jump 30.2% to $0.89, suggesting a market reassessment of its business model, potentially providing support for future financing and expansion.
- Increased Demand for Safe Assets: Growing concerns about Federal Reserve independence have led investors to shift towards safe-haven assets like gold, driving up precious metals stocks, which reflects market sensitivity to economic uncertainties and a preference for secure investments.
Continue Reading
Twist Bioscience Raises 2026 Revenue Guidance to $425M-$435M Amid Positive Market Outlook
- Rating Maintained: Barclays retains its Overweight rating on Twist Bioscience and raises the price target from $37 to $39, reflecting a positive outlook for the life sciences and diagnostics instruments sector, which is expected to outperform in 2026.
- Revenue Growth Forecast: Twist Bioscience anticipates total revenue between $425 million and $435 million for 2026, indicating a year-over-year increase of 13% to 15.5%, showcasing strong growth potential in the DNA synthesis and protein solutions segments.
- Segment Performance: The DNA Synthesis and Protein Solutions Group is projected to generate $194 million to $199 million, representing a 15% to 18% increase, while the NGS Applications Group is expected to achieve $231 million to $236 million, reflecting an 11% to 13.5% growth, highlighting robust development across multiple areas.
- Profitability Goals: Twist Bioscience expects a gross margin exceeding 52% for fiscal 2026 and aims to achieve adjusted EBITDA breakeven in the fourth quarter, indicating positive progress in profitability and financial health.
Continue Reading